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tion (FDA) for rifapentine and the Good Clinical Practice
(GCP) standards of the International Conference on Har-
monization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH). Clinical trial ex-
perts reviewed the protocol and costs were assessed based
on the Resource Based Relative Value Scale (RBRVS), ex-
pert opinion, and published prices for materials and ser-
vices. We constructed a model that summarized costs per
patient, per trial site, and per trial to implement the proto-
col. Entering the number of patients to be assessed, num-
ber of trial sites, number of trials, and anticipated drop out
rates generated estimated costs. The model calculated the
cost for all patients to complete the trial, costs associated
with screening patients who drop out immediately, and
savings that may be realized from patients dropping out
during the trial. These figures generated lower and upper
trial cost estimates. A 15% drop out rate at screening and
a 15% drop out rate during the trial was assumed.
RESULTS: For 850 to 1,000 patients to complete a Phase
III trial, 1,176 patients will need to be screened. The esti-
mated total cost (2000 US dollars) is between $22.3 mil-
lion and $22.6 million.
CONCLUSIONS: A Phase III clinical trial for a new pul-
monary TB drug will cost between $22.3 million and
$22.6 million, assuming a drop out rate no greater than
15% at screening and 15% over the course of the trial.
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OBJECTIVE: To assess the cost-effectiveness of Aldara
(Imiquimod) 5% topical cream versus other therapies for
the management of external genital warts (EGWs) in a
Dutch treatment environment.
METHODS: An economic model is presented that uti-
lizes a two-stage therapy sequence. Choice of initial and
subsequent therapy was based on the results of a recently
completed chart review of three dermatology clinics in
the Netherlands. This chart review provided valuable
guidance regarding treatment switching, resources used
(i.e. average number of patient visits) and costs associ-
ated with the management of EGWs. Sustained clearance
rates were incorporated into the economic model based
on published literature of key clinical trial results. Cost-
ing was based on nationally available cost estimates for
the Netherlands as costs based on chart reviews were site
specific and hence were not appropriate for use.
RESULTS: Estimated average costs per successful clearance
for Aldara plus cryotherapy were 1,128 DFL (€512) com-
pared with 1,455 DFL (€660) for the next most cost-effec-
tive therapy sequence—Condyline (first line) plus cryother-
apy (second line). In terms achieving the therapeutic target
of 50% clearance, only sequences in which Aldara was used
as first line therapy achieved this.
CONCLUSION: The results of the cost-effectiveness
analysis demonstrated that Aldara (as first line therapy)
plus cryotherapy (second line) was the most cost-effective
therapy sequence in the Netherlands.
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OBJECTIVE: To estimate costs and benefits of a preven-
tive influenza vaccination in a group of employees of Snam-
progetti (an Eni-group company), to define a scheme of
cost-benefit analysis to be used for other strategies of vacci-
nation and in other contexts.
METHODS: In an observational study conducted from
October 1999 to June 2000, 153 employees (about 10%
of the whole staff of Snamprogetti) voluntarily received
the vaccine, and were compared to 153 non-vaccinated
employees working in the same context and matched for
age and gender. The outcome was evaluated by checking
absentee records from the personnel department and de-
termining the causes, including influenza. Costs and ben-
efits of the influenza vaccination from the Snamprogetti
point of view were subsequently calculated.
RESULTS: The influenza vaccination strategy reduced
absence from work by 77% and has decreased the loss of
working days by 82%. The relationship between the ben-
efits of the vaccination strategy (less working days lost)
and its cost was 12.12. Convenience also becomes evi-
dent following sensitivity analysis, which considered the
mean cost of a working day for the employees enrolled,
and showed that the cost-benefit ratio was 9.45.
CONCLUSIONS: The results of this study suggest that
implementation of an influenza vaccination strategy in
Snamprogetti was cost effective. The cost-benefit analysis
used in this study could also be used for other vaccina-
tion strategies and in other contexts.
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OBJECTIVES: Influenza is a major cause of illness, pro-
ductivity loss, and work absenteeism among healthy work-
ing adults aged between 25 and 64 years. This group is not
